Delving into the Latest Updates on Metyrapone with Synapse

The purpose of this study is to determine the importance in the acute stress response induced by psilocybin (the primary component of "magic mushrooms") in facilitating positive outcomes. Participants in this study will be given psilocybin in combination with a placebo or metyrapone, a cortisol synthesis inhibitor medication, on four different occasions.

Start Date01 Sep 2025

Sponsor / Collaborator

University of Calgary

NCT06106295

/ RecruitingPhase 2IIT

Metyrapone Intervention in Patients With Mild Autonomous Cortisol Secretion (MACS)

The purpose of this study is to find out whether the study drug, metyrapone, is safe and effective in treating participants with Mild Autonomous Cortisol Secretion (MACS).

Start Date19 Dec 2023

Sponsor / Collaborator

Mayo Clinic

NCT05919992

/ CompletedEarly Phase 1IIT

The Role of Glucocorticoids to Maintain Energy Homeostasis During Starvation

In a randomized, cross-over study, 20 healthy volunteers will receive a block and replace therapy that mimics physiological GC rhythm (metyrapone plus hydrocortisone) or placebo. Participants will undergo two identical fasting periods with each treatment. With the block and replace therapy, fasting-induced GC peak will be suppressed. Metabolic and autonomic parameters will be compared to reveal whether GCs mediate the physiological adaptions to caloric restriction.
Understanding acute effects of GCs upon caloric restriction is critical, since repetitive disruptions of GC secretion may become harmful in chronic conditions.

Start Date15 May 2023

Sponsor / Collaborator

Universitätsspital Basel

100 Clinical Results associated with Metyrapone

Login to view more data

100 Translational Medicine associated with Metyrapone

Login to view more data

100 Patents (Medical) associated with Metyrapone

Login to view more data

4,663

Literatures (Medical) associated with Metyrapone

01 Apr 2025·Journal of Neuroendocrinology

Corticotropin‐releasing hormone receptor 1 mediates the enhanced locomotor activity and metabolic demands to an acute thermal stress in adult zebrafish

Article

Author: Vijayan, Mathilakath M. ; Shvartsburd, Zachary

AbstractWe recently showed that Crh‐Crhr1 signalling is essential for acute stress‐related locomotor activity in zebrafish larvae. However, the possibility that Crhr1 activation may also initiate the acute metabolic demands for stress coping was unexplored. Here, we tested the hypothesis that Crhr1 signalling is essential for the thermal stressor‐induced increases in the acute metabolic rate, a key response for coping with the enhanced energy demands during stress. We tested this by using a wildtype (WT) and a ubiquitous Crhr1 knockout (crhr1−/−) zebrafish and subjecting them to an acute thermal stressor (TS: +5°C above ambient for 60 min). The TS induced the heat shock proteins response in both genotypes, but the elevated cortisol response observed in the WT was absent in the crhr1−/− mutant. The TS also increased the locomotor activity and the metabolic rate in the WT fish, but this response was inhibited in the crhr1−/− mutants. To test if this was due to a lack of TS‐induced cortisol elevation in the crhr1−/− mutant, we mimicked the response in the WT fish by treating them with metyrapone, an 11β‐hydroxylase inhibitor. While metyrapone inhibited the TS‐induced cortisol elevation in the WT, it did not affect the metabolic rate. The lack of Crhr1 also reduced the swimming performance, and the lower Ucrit in the mutants corresponded with alterations in muscle energy metabolism. Together, our results indicate that Crh‐Crhr1 signalling, independent of downstream cortisol action, is essential for the TS‐induced acute hyperlocomotor activity and the associated increases in the metabolic demand for stress coping.

28 Mar 2025·Oxford Medical Case Reports

Ectopic ACTH-secreting pheochromocytoma without typical signs of Cushing syndrome

Article

Author: Martínez-Sánchez, Froylan D ; Solis-Coronado, Orlando D ; Mendoza-García, Jesús G ; Tenorio-Aguirre, Erika K ; Medina-Julio, David ; Soto-Montes, Zeltzin

AbstractThis case report describes a 42-year-old female with a rare pheochromocytoma presenting without classic Cushingoid features but with uncontrolled hypertension, type 2 diabetes, and recurrent headaches. Despite the absence of typical signs, biochemical analysis revealed elevated cortisol and ACTH levels, and imaging showed a 6 cm adrenal mass. The patient was stabilized preoperatively with alpha-blockers and metyrapone before undergoing a successful laparoscopic adrenalectomy. Histopathology confirmed pheochromocytoma with aggressive features. Postoperatively, her blood pressure and symptoms improved, and her cortisol levels normalized. This case underscores the diagnostic challenges of ACTH-secreting pheochromocytomas without classic hypercortisolism signs and emphasizes the need for thorough endocrine and imaging assessments. Surgical resection remains the definitive treatment, with long-term follow-up essential to monitor for recurrence. This case contributes to the limited literature on the coexistence of pheochromocytoma and ectopic ACTH secretion.

17 Mar 2025·JCEM Case Reports

Successful Medical Management of Cushing Disease With Metyrapone Throughout Pregnancy: A Report of 2 Cases

Article

Author: Theodorou, Angeliki ; Geer, Eliza B

AbstractCushing syndrome (CS) in pregnancy is a rare disorder with challenging diagnostic and therapeutic considerations. For patients with medically managed CS planning pregnancy, bilateral adrenalectomy is advised before conception. To our knowledge, no case of Cushing disease (CD) medically treated throughout pregnancy with cortisol synthesis inhibition has been described. We present 2 cases of CD in pregnancy managed with metyrapone, a non-Food and Drug Administration-approved drug for pregnancy. The first case involves a 31-year-old woman with recurrent CD who conceived twins via in vitro fertilization while on metyrapone. She had an uneventful pregnancy, delivering healthy twins at 37 weeks. Postpartum, she developed hypertension, which resolved spontaneously, and remained on metyrapone, with stable cortisol levels and normal development of her twins. The second case describes a 29-year-old woman with recurrent CD since adolescence, status post 2 transsphenoidal resections and gamma knife radiosurgery, who conceived naturally on metyrapone. After an uncomplicated pregnancy, she developed postpartum preeclampsia requiring temporary antihypertensive therapy. Both cases showed favorable maternal and fetal outcomes, highlighting metyrapone as a therapeutic option for managing CD during pregnancy.

5

News (Medical) associated with Metyrapone

10 Jul 2024

·www.esteve.com

ESTEVE ACQUIRES HRA PHARMA RARE DISEASES

ESTEVE has completed the acquisition of HRA Pharma Rare Diseases, a business specialized in rare diseases, from Perrigo Company plc. With this acquisition, ESTEVE expands its portfolio in rare and severe diseases adding, to the current existing offer, three new medications to treat Cushing's syndrome and adrenocortical carcinoma: Metopirone, Lysodren, and Ketoconazole HRA. HRA Pharma Rare Diseases has been a leading company for over 15 years in rare and severe diseases, providing the best care and services to individuals living with rare diseases, and is committed to supporting healthcare professionals worldwide. "This acquisition allows us to accelerate our international expansion, strengthening our global presence and ability to better address unmet needs, thus improving the lives of more people," highlights Staffan Schüberg, Chief Executive Officer of ESTEVE. With annual net revenues in 2023 of approximately 50 million euros, HRA Pharma Rare Diseases has a presence in numerous European countries and the United States with a team of 49 individuals. This agreement represents an investment of up to 275 million euros, structured with an initial fixed contribution and future variable payments tied to revenue. Share

Acquisition

26 Apr 2024

·firstwordpharma.com

Perrigo to divest rare diseases unit to Spain's Esteve for €275 million

Perrigo is offloading its HRA Pharma Rare Diseases business to Barcelona-based pharmaceutical company Esteve Healthcare for a total of up to €275 million ($294 million) and plans to use the proceeds to help pay down its debt.The transaction, which includes €190 million in cash upfront plus up to €85 million in potential earnouts if certain sales targets are reached, is expected to close in the third quarter.The unit's three-product portfolio includes the Cushing's syndrome treatments Metopirone (metyrapone) and ketoconazole, as well as Lysodren (mitotane), which is prescribed to treat adrenal cortical carcinoma. Staffan Schüberg, chief executive at Esteve, said the deal is "another step towards the company's vision of being an international and specialist pharma company."Meanwhile, Perrigo CEO Patrick Lockwood-Taylor said the divestment "further supports our position as a leading fast-moving consumer goods company," adding that the upfront cash proceeds would allow the company "to reduce net leverage to below 4.0x by the end of 2024."

AcquisitionDrug Approval

24 Apr 2024

·www.esteve.com

ESTEVE SIGNS A BINDING OFFER TO ACQUIRE HRA PHARMA RARE DISEASES, A PERRIGO COMPANY AFFILIATE

ESTEVE has signed a binding offer with Perrigo Company plc to acquire Perrigo's HRA Pharma Rare Diseases, a business specialized in rare and ultra-rare diseases, following the information and consultation process with HRA Pharma Works Council in France and subject to the satisfaction of customary closing conditions, including receipt of regulatory approvals. ESTEVE will increase its portfolio in the rare and severe diseases therapeutic area, adding to its current portfolio three new medicines that address Cushing's syndrome and Adrenocortical Carcinoma: Metopirone, Lysodren, and Ketoconazole HRA. HRA Pharma Rare Diseases has over 15 years' experience in rare and ultra-rare diseases and is dedicated to bringing the best care and services to people living with rare diseases and committed to supporting healthcare professionals all over the world. With annual Net Revenues in 2023 around €50M, the HRA Pharma Rare Diseases business has a presence in several European countries as well as in the US. "This transaction aims to advance ESTEVE on the path of covering the unmet patients' needs, in line with ESTEVE's purpose of improving people's lives and is another step towards the company's vision of being an international specialty pharma company", concludes Staffan Schüberg, Chief Executive Officer of ESTEVE. Patrick Lockwood-Taylor, Perrigo's President and Chief Executive Officer, states: "We are pleased that ESTEVE, with its track record of growth and international footprint, will look to increase global access to these effective treatment options for all those patients in need". The binding offer is for up to €275 million, consisting of an upfront payment and potential earnout payments. The closing of the transaction should take place during the third quarter of 2024, following the required works council consultation and subject to customary regulatory approvals. Perella Weinberg Partners and Clifford Chance served as ESTEVE's lead advisors on this transaction. Morgan Stanley & Co. LLC and Wachtell, Lipton, Rosen & Katz served as Perrigo's lead advisors on this transaction.

100 Deals associated with Metyrapone

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00410	Metyrapone	V04CD01	DB01011

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Adrenal Insufficiency	-	Novartis AG	30 May 2014
Cushing Syndrome	Australia	CHIESI Farmaceutici SpA	02 Aug 1991
Pituitary ACTH Hypersecretion	United States	HRA Pharma Rare Diseases SAS	04 Dec 1961

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Endogenous Cushing Syndrome	Discovery	Poland	HRA Pharma Development SARL	01 Apr 2015
Endogenous Cushing Syndrome	Discovery	Germany	HRA Pharma Development SARL	01 Apr 2015
Endogenous Cushing Syndrome	Discovery	Hungary	HRA Pharma Development SARL	01 Apr 2015
Endogenous Cushing Syndrome	Discovery	Belgium	HRA Pharma Development SARL	01 Apr 2015
Endogenous Cushing Syndrome	Discovery	Romania	HRA Pharma Development SARL	01 Apr 2015
Endogenous Cushing Syndrome	Discovery	Turkey	HRA Pharma Development SARL	01 Apr 2015
Endogenous Cushing Syndrome	Discovery	Spain	HRA Pharma Development SARL	01 Apr 2015
Endogenous Cushing Syndrome	Discovery	Italy	HRA Pharma Development SARL	01 Apr 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


LBSAT59 (ENDO2022)	Not Applicable	ACTH \| cortisol \| DHEAS	22	Metyrapone (Patients with OIAI)	aekfcifdrl(fixzjdqbph) = wgeeoamwxv huowxwzhbx (okffbxiqzt, 8.1 - 51) View more	-	01 Nov 2022
LBSAT59 (ENDO2022)	Not Applicable	ACTH \| cortisol \| DHEAS	22	Metyrapone (Patients without OIAI)	aekfcifdrl(fixzjdqbph) = wfaxlswbwv huowxwzhbx (okffbxiqzt, 5.9 - 55) View more	-	01 Nov 2022
NCT02297945 (PROMPT, ENDO2021)	Phase 3	Endogenous Cushing Syndrome 24 hours urine free cortisol (UFC)	50	Metyrapone	lhkutqluep(qcvjddfnpy) = inmqttypik hpkmaoauag (wepgyrqtts, 291 - 8476) View more	Positive	03 May 2021
ENDO2021	Not Applicable	Cushing Syndrome AM serum cortisol \| PM serum cortisol \| ACTH ... View more	-	Metyrapone	edndrcufhi(kgbuvcbglu) = swxvdwnttw ylynqbxaox (ktwbzefmoj ) View more	Positive	03 May 2021
ENDO2021	Not Applicable	Ectopic ACTH Syndrome \| Thyroid Cancer, Medullary \| Hypocalcemia ACTH \| calcitonin \| CEA	-	Selpercatinib	(yalzqlyccp) = kljoilhprl aofmskvpcp (wasatonnld ) View more	Positive	03 May 2021
ENDO2021	Not Applicable		-	Cabozantinib	(yalzqlyccp) = kdbyqlswpr aofmskvpcp (wasatonnld )	Positive	03 May 2021
MON-905 (ENDO2020)	Not Applicable	Pituitary ACTH Hypersecretion	-	Metyrapone 1,000 mg/day	nriceqfiom(opktsnptbu) = yyuxdjxfcj znjzeecfay (aqwljcgcjs ) View more	Positive	08 May 2020
MON-905 (ENDO2020)	Not Applicable	Pituitary ACTH Hypersecretion	-	Dexamethasone 0.1-10 nM	ohsmrznrmk(yeakftdtud) = pwhsvuffzh edfjedyznq (bacduwhxyw ) View more	Positive	08 May 2020
SAT-446 (ENDO2019)	Not Applicable	Prader-Willi Syndrome	45	Metyrapone (Adults with Prader-Willi Syndrome)	pfywugeiib(yyhhszyfnk) = snqvdtbuvx mdyheysywr (eeswxpisdz )	Positive	30 Apr 2019
SUN-LB068 (ENDO2019)	Not Applicable	Neuroendocrine Tumors \| Ectopic ACTH Syndrome	-	Metyrapone	(vbqneuqlyw) = ownqadsxzk fxsnedrprk (rkqkvbbpah ) View more	Positive	30 Apr 2019
ESPE2016	Not Applicable	Cushing Syndrome	-	Metyrapone	(ubqpmpvwyd) = dsvzvnsbrl pntrcxwxxt (gnzjckwoez )	-	10 Sep 2016
Pubmed \| J Clin Endocrinol Metab	Not Applicable	Cushing Syndrome	195	Metyrapone	kpwxhjegcf(guzfavajpq) = vwohzngsee tmgkihnrsx (ygaykkvkmq ) View more	Positive	01 Nov 2015
SFN2000	Not Applicable	Memory Disorders	-	Metyrapone 50 mg/kg	rkbcflbnez(bluuykpgdl) = dpvnefmhte rqemvjqarh (zyqldfwqun )	-	08 Nov 2000
SFN2000	Not Applicable	Memory Disorders	-	Vehicle	rkbcflbnez(bluuykpgdl) = bmakirjzzl rqemvjqarh (zyqldfwqun )	-	08 Nov 2000